Ginisortamab

Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors[1][2][3].

Product Specifications

CAS Number

[2390147-17-6]

Product Name Alternative

UCB6114

UNSPSC

12352203

Target

Dan family

Type

Inhibitory Antibodies

Related Pathways

TGF-beta/Smad

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ginisortamab.html

Purity

99.05

Solubility

10 mM in DMSO

Smiles

[Ginisortamab]

Molecular Weight

(147.56 kDa)

References & Citations

[1]Debashis Sarker, et al. A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors. Meeting Abstract, 2022 ASCO Gastrointestinal Cancers Symposium.|[2]Davies GCG, et al. Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer. MAbs. 2023 Jan-Dec;15 (1) :2289681.|[3]Debashis Sarker, et al. Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors. Cancer Res (2023) 83 (8_Supplement) : CT094 .